Lassen emerges from Frazier with over $31M and a mAb for fibrosis and cancer

Lassen debuts with mAb programs for cancer, fibrosis and deals with CSL, Fujifilm

After incubating in Frazier for a year and half, Lassen emerged from stealth Wednesday with a preclinical program targeting the IL-11 receptor that could be applied to both fibrosis and cancer and enough funds to complete initial human studies.

The San Diego-based antibody company was formed in January 2019 as part of Frazier Healthcare Partners’ company creation activities. In August, Frazier led Lassen Therapeutics’ $31

Read the full 649 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE